



JC530 U.S. PTO
09/521742
03/09/00

Kongeriget Danmark

Patent application No.: PA 1999 00336

Date of filing: 10 March 1999

Applicant: Biora BioEx AB
Per Albin Hanssons Väg 41
S-205 12 Malmö

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification, claims, sequence listing and drawings as filed with the application on the filing date indicated above.



Patent- og
Varemærkestyrelsen

Erhvervsministeriet

Taastrup 18 February 2000


Karin Schlichting
Head Clerk

MATRIX PROTEIN COMPOSITIONS FOR INDUCTION OF APOPTOSIS

FIELD OF INVENTION

5 The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides as therapeutic or prophylactic agents for inducing programmed cell death.

BACKGROUND OF THE INVENTION

10 Enamel matrix proteins such as those present in enamel matrix are best known as precursors of dental enamel. Enamel proteins and enamel matrix derivatives have previously been described in the patent literature to induce hard tissue formation (i.e. enamel formation, cf. US Patent No. 4,672,032 (Slavkin)) or binding between hard

15 tissues (EP-B-0 337 967 and EP-B-0 263 086). In recent animal studies using enamel matrix proteins for regeneration of tooth attachment, it has been observed that the regeneration and healing progresses with minimal signs of epithelial interference. This is in contrast to all other regenerative therapies of the periodontium where epithelial downgrowth from the oral cavity into the lesion is a common complication. To

20 investigate possible restrictive effects of enamel matrix proteins on epithelial cell growth, epithelial cells were cultured in the presence of enamel matrix proteins.

SUMMARY OF THE INVENTION

25 It has surprisingly been found that epithelial cancer cells (HeLa cells) which are not ameloblasts and which are not found in the periodontal environment and which do not participate in tooth development undergo apoptosis (programmed or induced cell death) when cultured in the presence of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins (in the following collectively termed "active enamel

30 substance"). Accordingly, the present invention relates to the use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the induction of apoptosis.

In another aspect, the present invention relates to method for inducing apoptosis in neoplastic cells, the method comprising applying an effective amount of an active enamel substance at or on neoplastic cells.

5 Apoptosis (programmed or induced cell death) is involved in the focal elimination of certain cells during normal development and in the turnover of cells in healthy adult tissues. Examples where apoptosis has been found to be involved are in organogenesis during embryonic life, e.g. the separation of digits during limb development, cusp and root formation during tooth development, elimination of worn-out cells in the small intestine, and clonal elimination of lymphocytes that might otherwise react with "self" antigens.

Recent evidence suggests that apoptosis may be equally important in the understanding of carcinogenesis and for developing novel therapies for different 15 neoplastic diseases. Thus, it has been shown that apoptosis is involved in preventing genome instability from developing in cells in which the cell cycle has been perturbed, and it is associated with injurious stimuli such as therapeutic irradiation and cytotoxic drugs used to treat malignant neoplasms.

20 Apoptosis is a gene-regulated process involving the synthesis of some proteins that promote apoptosis and others that protect against it. The presence of the tumour suppressor gene p53 is responsible for the initiation of apoptosis as a result of cell injury, in particular injury caused by DNA double-stranded breaks. In human cancer treatment, this is extremely important because tumour cells from which p53 is absent 25 do not undergo apoptosis when exposed to ionising radiation. In addition, lack of p53 is likely to result in the survival of cells in which DNA mutations have occurred and thus to increase the risk of development of cancer. Certain cells that have been deprived of growth promoting factors or whose growth have been arrested with cytotoxic drugs are rendered susceptible to apoptosis by expression of the proto- 30 oncogene c-myc. This gene encodes an essential part of the proliferative machinery of the cell, and deregulation of the expression of this gene is implicated in most neoplasms. Certain gene products protect cells from apoptosis. Examples of such gene products include those of the bcl-2 gene, the proto-oncogene c-abl and the LMP-1 gene of the Epstein-Barr virus.

A number of different pathways for induction of apoptosis have been demonstrated. Gamma irradiation acts directly on the chromosomes by causing DNA strand breaks. Certain hormones such as glucocorticoids induce apoptosis in thymocytes, probably

5 via a glucocorticoid receptor complex. A third induction pathway is via a direct contact with the plasma membrane of the target cells. An example of this is the effect of granzyme B which is released as part of the interaction of cytotoxic T-cells with a target cell.

10 In epithelial cells, apoptosis has been found to take place when cell adhesion to extracellular matrix by means of fibronectin and other extracellular proteins is blocked. In an immortalised thyroid cell line, it appeared that adhesion, spreading and cytoskeleton organisation were dependent on integrin-fibronectin interaction. It has been shown that cells become apoptotic when peptides containing the RGD (Arg-Gly-

15 Asp) motif inhibit binding of fibronectin to integrin receptors (cf. M. Vitale et al., *J. Clin. Endocrinol. Metab.* 83 (10), 1998, pp. 3673-3680). Similar findings have been reported for normal cells by, e.g., Z Zhang et al., *Proc. Natl. Acad. Sci. USA* 92 (13), 1995, pp. 6161-6165; HJ Kim et al., *Am. J. Physiol.* 271 (2 pt.1), 1996, pp. L277-286; G McGill et al., *J. Cell Biol.* 138 (4), 1997, pp. 901-911. Inhibition of adhesion

20 resulting in cell death not only happens to normal (non-transformed) cells, but has also been shown for melanoma cells. Thus, MD Mason et al., *J. R. Soc. Med.* 89 (7), 1996, pp. 393-395, reported that loss of integrin-mediated signalling induced apoptosis in melanoma cells within 3 days of treatment with a peptide containing the RGD motif blocking the alpha v beta 3 integrin. Furthermore, it has been shown that

25 the RGD motif is an integrin-recognition motif, and that peptides containing RGD induce apoptosis by activation of caspase-3 which is an enzyme that participates in a cascade resulting in disassembly of the cell (cf. CD Buckley et al., *Nature* 397, Feb. 1999, pp. 534-539).

30 Without wishing to be limited to any particular hypothesis, it is currently believed that the active enamel substance may exert its apoptosis inducing effect either by binding to cell surface receptors in an analogous manner to RGD so as to block the site needed for cellular adhesion to extracellular matrix, or by binding to cells surface

structures such as CD44 or integrins, thereby directly activating caspase 3 and triggering the apoptotic pathway described by Buckley et al., *supra*.

In developing teeth, the enamel is formed by a layer of epithelial cells called ameloblasts. These, in turn, are supported by another layer of epithelial cells providing the ameloblasts with growth factors and nutrients required for their continued existence and function. The ameloblasts synthesize and secrete enamel matrix proteins which, together with mineral and water, constitute the enamel matrix which is an early developmental stage of dental enamel. Enamel matrix proteins are mainly present during the secretory stage of enamel formation. After their initial deposition, they are gradually degraded and then lost as enamel development progresses. Also, during enamel development, apoptosis is observed in epithelial cells close to the enamel matrix. This apoptotic event is preceded by translocation of enamel matrix degradation products from the developing enamel into the enamel organ that is composed of epithelial cells. The active enamel substance observed to be useful in the present invention is composed of a number of proteins and peptides including such degradation products. These observations are also supported by studies of guinea pig molars showing that processing of enamel proteins is linked to the reduction of the number of surrounding epithelial cells (cf. Example 1 below).

20

DETAILED DESCRIPTION OF THE INVENTION

Apoptosis has attracted considerable interest for the potential treatment of cancers and neoplasms. The present inventors surprisingly observed that when human epithelial cancer cells (HeLa cells) were cultured in the presence of the active enamel substance they underwent apoptosis (*vide* Example 2 below). By way of comparison, human connective tissue cells (fibroblasts) cultured under similar conditions in the presence of the active enamel substance were stimulated as to growth. Based on these results, the present inventors believe that the active enamel substance may be used for the (selective) induction of apoptosis in neoplastic cells, specifically in the treatment, e.g. topical treatment, of certain types of cancer and benign, semi-malignant (i.e. locally invasive) or malignant neoplasms.

It is currently believed that the active enamel substance may be particularly beneficial for use in the treatment of epithelial derived cancers or neoplasms, as the results currently available appear to show that the active enamel substance exerts its apoptotic effect specifically on epithelial cells. In the use according to the present invention, it is therefore

5 preferred to apply the active enamel substance topically at or on affected tissue comprising a substantial proportion of epithelial cells. In particular, such tissue comprises skin or mucosal tissue. Mucosal tissue which may advantageously be treated with the active enamel substance in accordance with the invention comprises any tissue which presents a suitable surface available for topical application of the active enamel substance, either

10 naturally or following surgical incision. Examples of such mucosal surfaces are oral, gastrointestinal, respiratory tract (e.g. lung), cervical or abdominal mucosa.

Other tissues comprising a significant proportion of epithelial cells are glandular tissues, e.g. mammary gland, pancreas, liver, thyroid gland, bladder, prostate, sweat gland, salivary

15 gland or pituitary gland tissue.

On surgical removal of a tumour, it is important to reduce the risk that tumour cells migrate from the site of surgery to invade another part of the body. In a specific embodiment of the present invention, the active enamel substance is therefore applied at or on a tumour site

20 before, during or after surgical removal of a tumour or neoplastic tissue to substantially reduce the risk of postsurgical metastasis and/or to prevent recurrence of the tumour at the site of surgery.

Apart from the treatment of cancer or neoplastic tissue, it is contemplated that the active

25 enamel substance may be used for the prophylaxis or treatment of warts, in particular warts resulting from viral infection, e.g. papilloma or condyloma.

Enamel matrix, enamel matrix derivatives and enamel matrix proteins

30 Enamel matrix is a precursor to enamel and may be obtained from any relevant natural source, i.e. a mammal in which teeth are under development. A suitable source is developing teeth from slaughtered animals such as, e.g., calves, pigs or lambs. Another source is for example fish skin.

Enamel matrix can be prepared from developing teeth as described previously (EP-B-0 337 967 and EP-B-0 263 086). The enamel matrix is scraped off and enamel matrix derivatives are prepared, e.g. by extraction with aqueous solution such as a buffer, a dilute acid or base or a water/solvent mixture, followed by size exclusion, desalting or other purification 5 steps, optionally followed by freeze-drying. Enzymes may be deactivated by treatment with heat or solvents, in which case the derivatives may be stored in liquid form without freeze-drying.

In the present context, enamel matrix derivatives are derivatives of enamel matrix which 10 include one or several of enamel matrix proteins or parts of such proteins, produced naturally by alternate splicing or processing, or by either enzymatic or chemical cleavage of a natural length protein, or by synthesis of polypeptides in vitro or in vivo (recombinant DNA methods or cultivation of diploid cells). Enamel matrix protein derivatives also include 15 enamel matrix related polypeptides or proteins. The polypeptides or proteins may be bound to a suitable biodegradable carrier molecule, such as polyamino acids or polysaccharides, or combinations thereof. Furthermore, the term enamel matrix derivatives also encompasses synthetic analogous substances.

Proteins are biological macromolecules constituted by amino acid residues linked together 20 by peptide bonds. Proteins, as linear polymers of amino acids, are also called polypeptides. Typically, proteins have 50-800 amino acid residues and hence have molecular weights in the range of from about 6,000 to about several hundred thousand Daltons or more. Small proteins are called peptides or oligopeptides.

25 Enamel matrix proteins are proteins which normally are present in enamel matrix, i.e. the precursor for enamel (Ten Cate: Oral Histology, 1994; Robinson: Eur. J. Oral Science, Jan. 1998, 106 Suppl. 1:282-91), or proteins which can be obtained by cleavage of such proteins. In general such proteins have a molecular weight below 120,000 daltons and include amelogenins, non-amelogenins, proline-rich non-amelogenins, amelins (ameloblastin, sheathlin) and tuftelins.

30 Examples of proteins for use according to the invention are amelogenins, proline-rich non-amelogenins, tuftelin, tuft proteins, serum proteins, salivary proteins, amelin, enamelin, ameloblastin, sheathlin, and derivatives thereof, and mixtures thereof. A preparation 35 containing an active enamel substance for use according to the invention may also contain

at least two of the aforementioned proteinaceous substances. A commercial product comprising amelogenins and possibly other enamel matrix proteins is marketed as EMDOGAIN® (Biora AB).

5 In general, the major proteins of an enamel matrix are known as amelogenins. They constitute about 90% w/w of the matrix proteins. The remaining 10% w/w includes proline-rich non-amelogenins, tuftelin, tuft proteins, serum proteins and at least one salivary protein; however, other proteins may also be present such as, e.g., amelin (ameloblastin, sheathlin) which have been identified in association with enamel matrix. Furthermore, the 10 various proteins may be synthesized and/or processed in several different sizes (i.e. different molecular weights). Thus, the dominating proteins in enamel matrix, amelogenins, have been found to exist in several different sizes which together form supramolecular aggregates. They are markedly hydrophobic substances which under physiologically conditions form aggregates. They may carry or be carriers for other proteins or peptides.

15

Other protein substances are also contemplated to be suitable for use according to the present invention. Examples include proteins such as proline-rich proteins and polyproline. Other examples of substances which are contemplated to be suitable for use according to the present invention are aggregates of such proteins, of enamel matrix derivatives and/or 20 of enamel matrix proteins as well as metabolites of enamel matrix, enamel matrix derivatives and enamel matrix proteins. The metabolites may be of any size ranging from the size of proteins to that of short peptides.

As mentioned above, the proteins, polypeptides or peptides for use according to the 25 invention typically have a molecular weight of at the most about 120 kDa such as, e.g., at the most 100 kDa, 90 kDa, 80 kDa, 70 kDa or 60 kDa as determined by SDS Page electrophoresis. As indicated above, epithelial cells associated with ameloblasts are believed to be induced to undergo apoptosis by degradation products migrating from the enamel matrix during dental enamel development. Such degradation products, which 30 generally have a molecular weight between about 3 kDa and 25 kDa, such as between 5 kDa and 20 kDa, may be particularly effective for use according to the present invention.

The proteins for use according to the invention are normally presented in the form of a preparation, wherein the protein content of the active enamel substance in the preparation 35 is in a range of from about 0.05% w/w to 100% w/w such as, e.g., about 5-99% w/w, about

10-95% w/w, about 15-90% w/w, about 20-90% w/w, about 30-90% w/w, about 40-85% w/w, about 50-80% w/w, about 60-70% w/w, about 70-90% w/w, or about 80-90% w/w.

A preparation of an active enamel substance for use according to the invention may also
5 contain a mixture of proteins with different molecular weights.

The proteins of an enamel matrix can be divided into a high molecular weight part and a low molecular weight part, and it has been found that a well-defined fraction of enamel matrix proteins possesses valuable properties with respect to treatment of periodontal
10 defects (i.e. periodontal wounds). This fraction contains acetic acid extractable proteins generally referred to as amelogenins and constitutes the low molecular weight part of an enamel matrix (cf. EP-B-0 337 967 and EP-B-0 263 086).

As discussed above the low molecular weight part of an enamel matrix has a suitable
15 activity for inducing binding between hard tissues in periodontal defects. In the present context, however, the active proteins are not restricted to the low molecular weight part of an enamel matrix. At present, preferred proteins include enamel matrix proteins such as amelogenin, amelin, tuftelin, etc. with molecular weights (as measured in vitro with SDS-PAGE) below about 60,000 daltons but proteins having a molecular weight above 60,000
20 daltons have also promising properties as candidates for wound healing, anti-bacterial and/or anti-inflammatory agents.

Accordingly, it is contemplated that the active enamel substance for use according to the invention has a molecular weight of up to about 40,000 such as, e.g. a molecular weight of
25 between about 5,000 and about 25,000.

Within the scope of the present invention are also peptides as described in WO 97/02730, i.e. peptides which comprise at least one sequence element selected from the group consisting of the tetrapeptides DGEA (Asp-Gly-Glu-Ala), VTKG (Val-Thr-Lys-Gly), EKGE
30 (Glu-Lys-Gly-Glu) and DKGE (Asp-Lys-Gly-Glu) and which further comprise an amino acid sequence from which a consecutive string of 20 amino acids is identical to a degree of at least 80% with a string of amino acids having the same length selected from the group consisting of the amino acid sequence shown in SEQ ID NO:1 and a sequence consisting of amino acids 1 to 103 of SEQ ID NO:1 and amino acids 6 to 324 of SEQ ID
35 NO:2.

By the term "sequence identity" is meant the identity in sequence of amino acids in the match with respect to identity and position of the amino acids of the peptides. A gap is counted as non-identity for one or more amino acids as appropriate.

5

Such peptides may comprise from 6 to 300 amino acids, e.g. at least 20 amino acids, at least 30 amino acids, such as at least 60 amino acids, at least 90 amino acids, at least 120 amino acids, at least 150 amino acids or at least 200 amino acids.

10 A method for the isolation of enamel matrix proteins involves extraction of the proteins and removal of calcium and phosphate ions from solubilized hydroxyapatite by a suitable method, e.g. gel filtration, dialysis or ultrafiltration (see e.g. Janson, J-C & Rydén, L. (Eds.), Protein purification, VCH Publishers 1989 and Harris, ELV & Angal, S., Protein purification methods - A practical approach, IRL Press, Oxford 1990).

15

A typical lyophilized protein preparation may mainly or exclusively up to 70-90% contain amelogenins with a molecular weight (MW) between 40,000 and 5,000 daltons, the 10-30% being made up of smaller peptides, salts and residual water. The main protein bands are at 20 kDa, 12-14 kDa and around 5 kDa.

20

By separating the proteins, e.g. by precipitation, ion-exchange chromatography, preparative electrophoresis, gel permeation chromatography, reversed phase chromatography or affinity chromatography, the different molecular weight amelogenins can be purified.

25

The combination of molecular weight amelogenins may be varied, from a dominating 20 kDa compound to an aggregate of amelogenins with many different molecular weights between 40 and 5 kDa, and to a dominating 5 kDa compound. Other enamel matrix proteins such as amelin, tuftelin or proteolytic enzymes normally found in enamel matrix, 30 can be added and carried by the amelogenin aggregate.

As an alternative source of the enamel matrix derivatives or proteins one may also use generally applicable synthetic routes well-known for a person skilled in the art or use cultivated cells or bacteria modified by recombinant DNA-techniques (see, e.g., Sambrook, 35 J. et al.: Molecular Cloning, Cold Spring Harbor Laboratory Press, 1989).

Physico-chemical properties of enamel matrix, enamel matrix derivatives and enamel matrix proteins

5 In general the enamel matrix, enamel matrix derivatives and enamel matrix proteins are hydrophobic substances, i.e. less soluble in water especially at increased temperatures. In general, these proteins are soluble at non-physiological pH values and at a low temperature such as about 4-20°C, while they will aggregate and precipitate at body temperature (35-37°C) and neutral pH.

10

At least a part of the active enamel substance may be in the form of aggregates or is capable of forming aggregates after application *in vivo*. The particle size of the aggregates is in a range of from about 20 nm to about 1 µm.

15 It is contemplated that the solubility properties of the active enamel substance are of importance in connection with the prophylactic and therapeutic activity of the substance. When a composition containing the active enamel substance is administered to e.g. a human, the proteinaceous substances will precipitate due to the pH normally prevailing under physiological conditions. Thus, a layer of active enamel substance is formed at the 20 application site and this layer (which also may be a molecular layer in those cases where aggregates have been formed) is difficult to rinse off under physiological conditions. Furthermore, due to the substances bioadhesive properties (see below) the precipitated layer is firmly bound to the tissue also at the margin between the precipitated layer and the tissue. The proteinaceous layer thus covers the tissue onto which the active enamel 25 substance or compositions thereof have been applied and the active enamel substances are maintained *in situ* for a prolonged period of time, i.e. it is not necessary to administer the active enamel substance(s) with short intervals. Furthermore, the layer formed *in situ* can almost be compared to an occlusive dressing, i.e. the layer formed protects the tissue onto which the layer is formed from the surroundings.

30

In order to enable a proteinaceous layer to be formed *in situ* after application it may be advantageous to incorporate a suitable buffer substance in a pharmaceutical composition of the active enamel substance; the purpose of such a buffer substance could be to avoid the dissolution of the active enamel substance at the application site.

35

The active enamel substance has also been observed (by the present inventors) to possess bioadhesive properties, i.e. it has an ability to adhere to skin or mucosal surfaces. These properties are most valuable in connection with a therapeutic and/or prophylactic treatment at least for the following reasons:

5

- the prophylactically and/or therapeutically active substance(s) can be maintained at the application site for a prolonged period of time (i.e. i) the administration frequency can be reduced, ii) a controlled release effect of the active substance is obtainable and/or iii) a local treatment at the application site is improved)

10

- the active enamel substance may in itself be suitable as a vehicle for other prophylactically or therapeutically active substances because a vehicle containing the active enamel substance can be formulated as a bioadhesive vehicle (i.e. a novel bioadhesive drug delivery system based on the bioadhesive properties of the active

15

enamel substance).

Pharmaceutical compositions

For the administration to an individual (an animal or a human) the active enamel substance

20 and/or a preparation thereof are preferably formulated into a pharmaceutical composition containing the active enamel substance and, optionally, one or more pharmaceutically acceptable excipients.

The compositions may be in form of, e.g., solid, semi-solid or fluid compositions such as,

25 e.g.,

bioabsorbable patches, drenches, dressings, hydrogel dressings, hydrocolloid dressings, films, foams, sheets, bandages, plasters, delivery devices, implants,

30 powders, granules, granulates, capsules, agarose or chitosan beads, tablets, pills, pellets, microcapsules, microspheres, nanoparticles,

sprays, aerosols, inhalation devices,

35 gels, hydrogels, pastes, ointments, creams, soaps, suppositories, vagitories,

solutions, dispersions, suspensions, emulsions, mixtures, lotions, enemas,

kits containing e.g. two separate containers, wherein the first one of the containers

5 contains the active enamel substance optionally admixed with other active drug substance(s) and/or pharmaceutically acceptable excipients and the second container containing a suitable medium intended to be added to the first container before use in order to obtain a ready-to-use composition;

10 and in other suitable forms such as, e.g., implants or coating of implants or in a form suitable for use in connection with implantation or transplantation.

Compositions for application to the skin or to the mucosa are considered most important in connection with the present invention. Thus, a composition comprising the active enamel

15 substance to be administered may be adapted for administration by any suitable route, for example by topical (dermal), oral, buccal, nasal, aural, rectal or vaginal administration, or by administration to a body cavity such as, e.g., a tooth root or a tooth root canal. Furthermore, a composition may be adapted to administration in connection with surgery, e.g. in connection with excision of tumours or neoplastic tissue.

20

As mentioned above, a composition of the active enamel substance may be suitable for use during surgery, e.g. for topical application in the form of a gel, film or dry pellet, or as a rinsing solution or treatment with a paste or cream on tissue or surfaces.

25 The compositions may be formulated according to conventional pharmaceutical practice, see, e.g., "Remington's Pharmaceutical Sciences" and "Encyclopedia of Pharmaceutical Technology", edited by Swarbrick, J. & J. C. Boylan, Marcel Dekker, Inc., New York, 1988.

A pharmaceutical composition comprising an active enamel substance serves as a drug 30 delivery system. In the present context the term "drug delivery system" denotes a pharmaceutical composition (a pharmaceutical formulation or a dosage form) which upon administration presents the active substance to the body of a human or an animal. Thus, the term "drug delivery system" embraces plain pharmaceutical compositions such as, e.g., creams, ointments, liquids, powders, tablets, etc. as well as more sophisticated 35 formulations such as sprays, plasters, bandages, dressings, devices, etc.

Apart from the active enamel substance, a pharmaceutical composition for use according to the invention may comprise pharmaceutically acceptable excipients.

5 A pharmaceutically acceptable excipient is a substance which is substantially harmless to the individual to which the composition is to be administered. Such an excipient normally fulfils the requirements given by the national health authorities. Official pharmacopoeias such as e.g. the British Pharmacopoeia, the United States of America Pharmacopoeia and The European Pharmacopoeia set standards for pharmaceutically acceptable excipients.

10

Whether a pharmaceutically acceptable excipient is suitable for use in a pharmaceutical composition is generally dependent on which kind of dosage form is chosen for use for a particular kind of wound. In the following are given examples of suitable pharmaceutically acceptable excipients for use in different kinds of compositions for use according to the

15 invention.

In the following is given a review on relevant pharmaceutical compositions for use according to the invention. The review is based on the particular route of administration.

However, it is appreciated that in those cases where a pharmaceutically acceptable

20 excipient may be employed in different dosage forms or compositions, the application of a particular pharmaceutically acceptable excipient is not limited to a particular dosage form or of a particular function of the excipient.

The choice of pharmaceutically acceptable excipient(s) in a composition for use according
25 to the invention and the optimum concentration thereof cannot generally be predicted and must be determined on the basis of an experimental evaluation of the final composition.

However, a person skilled in the art of pharmaceutical formulation can find guidance in e.g., "Remington's Pharmaceutical Sciences", 18th Edition, Mack Publishing Company, Easton, 1990.

30

Topical compositions

For application to the mucosa or the skin, the compositions for use according to the invention may contain conventionally non-toxic pharmaceutically acceptable carriers and 5 excipients including microspheres and liposomes.

The compositions for use according to the invention include all kinds of solid, semi-solid and fluid compositions. Compositions of particular relevance are e.g. pastes, ointments, hydrophilic ointments, creams, gels, hydrogels, solutions, emulsions, suspensions, lotions, 10 liniments, shampoos, jellies, soaps, sticks, sprays, powders, films, foams, pads, sponges (e.g. collagen sponges), pads, dressings (such as, e.g., absorbent wound dressings), drenches, bandages, plasters and transdermal delivery systems.

The pharmaceutically acceptable excipients may include solvents, buffering agents, 15 preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, ointment bases, penetration enhancers, perfumes, and skin protective agents.

Examples of solvents are e.g. water, alcohols, vegetable or marine oils (e.g. edible oils like 20 almond oil, castor oil, cacao butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppyseed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, and teaseed oil), mineral oils, fatty oils, liquid paraffin, polyethylene glycols, propylene glycols, glycerol, liquid polyalkylsiloxanes, and mixtures thereof.

25 Examples of buffering agents are e.g. citric acid, acetic acid, tartaric acid, lactic acid, hydrogenphosphoric acid, diethylamine etc.

Suitable examples of preservatives for use in compositions are parabens, such as methyl, 30 ethyl, propyl p-hydroxybenzoate, butylparaben, isobutylparaben, isopropylparaben, potassium sorbate, sorbic acid, benzoic acid, methyl benzoate, phenoxyethanol, bronopol, bronidox, MDM hydantoin, iodopropynyl butylcarbamate, EDTA, benzalconium chloride, and benzylalcohol, or mixtures of preservatives.

Examples of humectants are glycerin, propylene glycol, sorbitol, lactic acid, urea, and 35 mixtures thereof.

Examples of chelating agents are sodium EDTA and citric acid.

Examples of antioxidants are butylated hydroxy anisole (BHA), ascorbic acid and
5 derivatives thereof, tocopherol and derivatives thereof, cysteine, and mixtures thereof.

Examples of emulsifying agents are naturally occurring gums, e.g. gum acacia or gum
tragacanth; naturally occurring phosphatides, e.g. soybean lecithin; sorbitan monooleate
derivatives; wool fats; wool alcohols; sorbitan esters; monoglycerides; fatty alcohols; fatty
10 acid esters (e.g. triglycerides of fatty acids); and mixtures thereof.

Examples of suspending agents are e.g. celluloses and cellulose derivatives such as, e.g.,
carboxymethyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose,
hydroxypropylmethylcellulose, carragenan, acacia gum, arabic gum, tragacanth, and
15 mixtures thereof.

Examples of gel bases, viscosity-increasing agents or components which are able to take
up exudate from a wound are: liquid paraffin, polyethylene, fatty oils, colloidal silica or
aluminium, zinc soaps, glycerol, propylene glycol, tragacanth, carboxyvinyl polymers,
20 magnesium-aluminium silicates, Carbopol®, hydrophilic polymers such as, e.g. starch or
cellulose derivatives such as, e.g., carboxymethylcellulose, hydroxyethylcellulose and other
cellulose derivatives, water-swellable hydrocolloids, carragenans, hyaluronates (e.g.
hyaluronate gel optionally containing sodium chloride), and alginates including propylene
glycol aginate.

25

Examples of ointment bases are e.g. beeswax, paraffin, cetanol, cetyl palmitate, vegetable
oils, sorbitan esters of fatty acids (Span), polyethylene glycols, and condensation products
between sorbitan esters of fatty acids and ethylene oxide, e.g. polyoxyethylene sorbitan
monooleate (Tween).

30

Examples of hydrophobic or water-emulsifying ointment bases are paraffins, vegetable oils,
animal fats, synthetic glycerides, waxes, lanolin, and liquid polyalkylsiloxanes.

Examples of hydrophilic ointment bases are solid macrogols (polyethylene glycols).

35

Other examples of ointment bases are triethanolamine soaps, sulphated fatty alcohol and polysorbates.

Examples of powder components are: alginate, collagen, lactose, powder which is able to 5 form a gel when applied to a surgical wound (absorbs liquid/wound exudate). Normally, powders intended for application on large open wounds must be sterile and the particles present must be micronized.

Examples of other excipients are polymers such as carmelose, sodium carmelose, 10 hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, pectin, xanthan gum, locust bean gum, acacia gum, gelatin, carboomer, emulsifiers like vitamin E, glyceryl stearates, cetanyl glucoside, collagen, carrageenan, hyaluronates and alginates and chitosans.

15 Dressings and/or bandages are also important delivery systems for the active enamel substance. When dressings are used as dosage form, the active enamel substance may be admixed with the other ingredients before or during the manufacture of the dressing or the active enamel substance may in some way be coated onto the dressing e.g. by dipping the dressing in a solution or dispersion of the active enamel substance or by spraying a 20 solution or dispersion of the active enamel substance onto the dressing. Alternatively, the active enamel substance may be applied in the form of a powder to the dressing. Dressings may be in the form of absorbent wound dressings for application to exuding 25 wounds. Dressings may also be in the form of hydrogel dressings (e.g. cross-linked polymers such as, e.g. Intrasite® which contains carboxymethylcellulose, propylene glycol or polysaccharide, disaccharide and proteins) or in the form of occlusive dressings such as, e.g., alginates, chitosan, hydrophilic polyurethane film, collagen sheets, plates, powders, foams, or sponges, foams (e.g. polyurethane or silicone), hydrocolloids (e.g. carboxymethylcellulose, CMC), collagen and hyaluronic acid-based dressings including combinations thereof.

30 The compositions mentioned above for topical administration are most suitably for application directly to wounds or they may be suitable for application to or for introduction into relevant orifice(s) of the body, e.g. the rectal, urethral, vaginal, aural, nasal or oral orifices. The composition may simply be applied directly on the part to be treated such as, 35 e.g., on the mucosa, or by any convenient route of administration.

Compositions which have proved to be of importance in connection with topical application are those which have thixotropic properties, i.e. the viscosity of the composition is affected e.g. by shaking or stirring so that the viscosity of the composition at the time of

5 administration can be reduced and when the composition has been applied, the viscosity increases so that the composition remains at the application site.

Compositions for application to mucosa or skin

10 Suitable compositions for use according to the invention may also be presented in the form of suspensions, emulsions or dispersions. Such compositions contain the active enamel substance in admixture with a dispersing or wetting agent, suspending agent, and/or one or more preservatives and other pharmaceutically acceptable excipients. Such compositions may also be suitable for use in the delivery of the active enamel substance to e.g. an intact 15 or damaged mucosa such as the oral, buccal, nasal, rectal, or vaginal mucosa, or for administration to intact or damaged skin, or wounds.

Suitable dispersing or wetting agents are, for example, naturally occurring phosphatides, e.g., lecithin, or soybean lecithin; condensation products of ethylene oxide with e.g. a fatty 20 acid, a long chain aliphatic alcohol, or a partial ester derived from fatty acids and a hexitol or a hexitol anhydride, for example polyoxyethylene stearate, polyoxyethylene sorbitol monooleate, polyoxyethylene sorbitan monooleate, etc.

Suitable suspending agents are, e.g., naturally occurring gums such as, e.g., gum acacia, 25 xanthan gum, or gum tragacanth; celluloses such as, e.g., sodium carboxymethylcellulose, microcrystalline cellulose (e.g. Avicel® RC 591, methylcellulose); alginates and chitosans such as, e.g., sodium alginate, etc.

Suitable examples of preservatives for use in compositions according to the invention are 30 the same as those mentioned above.

Rectal and/or vaginal compositions

For application to the rectal or vaginal mucosa, suitable compositions according to the invention include suppositories (emulsion or suspension type), enemas, and rectal gelatin capsules (solutions or suspensions). Appropriate pharmaceutically acceptable suppository bases include cocoa butter, esterified fatty acids, glycerinated gelatin, and various water-soluble or dispersible bases like polyethylene glycols and polyoxyethylene sorbitan fatty acid esters. Various additives like, e.g., enhancers or surfactants may be incorporated.

10 *Nasal or pulmonary compositions*

For application to the nasal or pulmonary mucosa (as well as to the oral mucosa), sprays and aerosols for inhalation are suitable compositions according to the invention. In a typical composition, the active enamel substance is present in the form of a particulate formulation optionally dispersed in a suitable vehicle. The pharmaceutically acceptable vehicles and excipients and optionally other pharmaceutically acceptable materials present in the composition such as diluents, enhancers, flavouring agents, preservatives, etc. are all selected in accordance with conventional pharmaceutical practice in a manner understood by the persons skilled in the art of formulating pharmaceuticals.

20

Dosages of enamel matrix, enamel matrix derivatives and enamel matrix proteins

In a pharmaceutical composition for use according to the invention, an active enamel substance is generally present in a concentration ranging from about 0.01% to about 25 99.9% w/w. The amount of composition applied will normally result in an amount of total protein per cm² area of affected tissue corresponding to from about 0.01 mg/cm² to about 20 mg/cm² such as from about 0.1 mg/cm² to about 15 mg/cm².

The amount applied of the composition depends on the concentration of the active enamel substance in the composition and of the release rate of the active enamel substance from the composition, but is generally in a range corresponding to at the most about 15-20 mg/cm².

In those cases where the active enamel substance is administered in the form of a fluid 35 composition, the concentration of the active enamel substance in the composition is in a

range corresponding to from about 0.1 to about 50 mg/ml. Higher concentrations are in some cases desirable and can also be obtained such as a concentration of at least about 100 mg/ml.

- 5 The concentration of the active enamel substance in a pharmaceutical composition depends on the specific enamel substance, its potency, the severity of the disease to be prevented or treated, and the age and condition of the patient. Methods applicable to selecting relevant concentrations of the active enamel substance in the pharmaceutical composition are well known to a person skilled in the art and may be performed according
- 10 to established guidelines for good clinical practice (GCP) or Investigational New Drug Exemption ("IND") regulations as described in e.g. International Standard ISO/DIS 14155 Clinical investigation of medical devices, 1994 and ICH (International Committee for Harmonisation): Harmonised tripartite guideline for good clinical practice, Brookwood Medical Publications, Ltd, Surrey, UK, 1996. A person skilled in the art would, by use of the
- 15 methods described in standard textbooks, guidelines and regulations as described above as well as common general knowledge within the field, be able to select the exact dosage regimen to be implemented for any active enamel substance and/or selected other active substances and dosage form using merely routine experimentation procedures.
- 20 In accordance with the present invention, application of the active enamel substance at or on tumorous tissue may suitably be combined with other forms of tumour treatment, such as surgery, administration of chemotherapeutic agents and/or radiation therapy of affected tissue.
- 25 The invention is further described in the following examples which are not in any way intended to limit the scope of the invention as claimed.

EXPERIMENTAL SECTION

- 30 Enamel Matrix Derivative, EMDOGAIN®, from BIORA AB, S-205 12 Malmö, Sweden containing 30 mg freeze-dried enamel matrix protein (in the following abbreviated to EMD) and 1 ml vehicle solution (Propylene Glycol Alginate), which are mixed prior to application, unless the protein and the vehicle are tested separately. The weight ratio is about 85/5/10
- 35 between the main protein peaks at 20, 14 and 5 kDa, respectively.

Example 1**Apoptosis in guinea pig dental epithelium**

5

Tissue preparation

Two guinea pigs of 200-250 g were anesthetized by carbon dioxide and decapitated.

Bilateral maxilla and mandible were dissected and fixed with freshly prepared 4%

- 10 paraformaldehyde in 0.1M phosphate buffer, pH 7.4, at 4°C. After fixation, the specimens were decalcified with neutral buffered 10% EDTA, dehydrated with graded ethanol, and embedded in paraffin. Sections (7 µm) were taken in the following directions: sagittal (mesio-distal) sections to obtain information about the changes in the enamel epithelium in association with the formation of the cementum pearls that are formed on the enamel
- 15 surface, bucco-lingual sections to obtain information about changes in the epithelial root sheath that take place when dentin and cementum are formed at the apical end of the molars, horizontal sections to follow the distribution of the epithelium around the molars. These sections were used for immunohistochemical demonstration of the epithelial cells and their basal lamina as well as the possible occurrence of apoptosis. Some sections
- 20 were stained with hematoxylin and eosin (H&E).

Immunohistochemical detection of laminin and keratin

The sections were pretreated with 2% hydrogen peroxide to diminish endogenous

- 25 peroxidase, incubated with 0.1% protease (Sigma, St.Louis, USA) for 15 min, and non-specific reaction was blocked with 4% normal goat serum (Dako, Copenhagen, Denmark). Then, they were incubated with rabbit anti-laminin antibody (1:1000, Dako, Copenhagen, Denmark) or mouse monoclonal anti-cytokeratin antibody (1:100, Boehringer-Mannheim, Germany) at 4°C overnight, rinsed with TBS (50 mM Tris buffer saline, pH 7.4), incubated
- 30 with goat anti-rabbit antibody with HRP (Dako, Copenhagen, Denmark) or goat anti-mouse antibody with HRP diluted to 1:100 (Dako, Copenhagen, Denmark) at room temperature for 60 min. The immunoreaction was visualized with 0.1% DAB (diamino benzidine), TBS were substituted for the primary antibodies in controls.

TUNEL procedure for the visualization of apoptosis

The sections were deparaffinized with xylene, rehydrated with graded ethanol, and rinsed with PBS (phosphate-buffered saline, 50 mM sodium phosphate, 200 mM NaCl, pH 7.4).

5 The sections were incubated with proteinase K (20 µg/ml in PBS, pH 7.4, Sigma, St.Louis, USA) for 15 min. at 37°C to expose the DNA strands, and rinsed with PBS. Endogenous peroxidase was blocked by 2.0% hydrogen peroxide in PBS for 5 min. at room temperature, DIG labeled dUTP (deoxyuridine triphosphate) solution and TdT (terminal deoxynucleotidyl transferase) were mixed to make TUNEL mixture (Oncor, Gaithersburg, MD). The sections were incubated with TUNEL mixture for 60 min. at 37°C. DIG labeled dUTP solution without TdT (terminal deoxynucleotidyl transferase) was used as negative control. After incubation, the specimens were rinsed with PB S and reacted with anti-Digoxigenin-peroxidase for 30 min. at room temperature. The reaction was visualized by 0.1% DAB with 0-02% hydrogen peroxide in PBS at room temperature. For positive controls, a mandible and a spleen of rats was observed in the same manner. Apoptotic cells were distributed in a part of incisal ameloblasts of transition-stage and a part of disintegrated enamel epithelium from FIRS in rat molars. Apoptotic cells were scattered in the spleen of a rat.

20 *Results*

The immunohistochemistry with antibodies against keratin showed the epithelial cells in all positions where they could be identified by means of ordinary light microscopy. In addition it was possible to distinguish epithelial cells in areas where cells of the enamel organ or the 25 epithelial root sheath were mingled with mesenchymal cells of the dental follicle. Immunohistochemistry with antibodies against laminin showed that the epithelial structures were associated with a basement membrane in some areas and that a basement membrane was missing in others. The TUNEL method visualized apoptotic bodies in specific regions of the contiguously growing teeth.

30 It was observed that ameloblasts underwent apoptosis in early secretory stage, transition stage, maturation stage and reduced enamel epithelial stage. Apoptosis in maturation stage and reduced enamel epithelial stage appeared to be associated with the formation of cementum pearls. At the apical area of the cartilage-like cementum, the enamel organ 35 which had a large stellate reticulum and lacked the distinct border of outer enamel

epithelium was observed. Apoptosis of enamel epithelium was observed in the same portions as those of cementum pearls. Based on these results, it is considered likely that apoptosis plays an important part in the reduction, transformation, evacuation and migration of enamel epithelium, which is an important step for the formation of cementum 5 during tooth development.

Example 2

10 Growth of human epithelial cells in the presence and absence of EMD

Materials and Methods

Human epithelial cells (HeLa; a human cervical cancer cell line) were obtained from 15 BioWhittaker, HeLa 07-229c, Lot # 8c2720. The cells were grown in Modified Eagle's Medium supplemented with 10% fetal calf serum. EMD was supplied by surface coating culture dishes with a 0.1% EMD solution in 0.1% HAc, and by supplementing the culture medium with 100 µl EMD per ml of medium. HeLa cells cultured under similar conditions in the absence of EMD were used as controls. All experiments were initiated with 50,000 cells 20 per ml of culture medium.

Results

(a) HeLa cells were grown in cultures for 24, 48, 72, 96 and 120 hours. Cultures were then 25 washed with PBS and cells were counted in the microscope using a fixed grid. Five different areas were counted in each of six parallel cultures at each timepoint. As appears from Fig. 1, HeLa cells show a marked decrease in cell density from 48 hours when grown in the presence of EMD.

30 (b) HeLa cells were cultured for 24 or 120 hours, washed twice with PBS and centrifuged. 100 µl of cells from each culture (n=6 at each timepoint/experiment) were then lysed, and released intracellular cAMP was measured by competitive enzyme immunoassay (EIA) using an Amersham Pharmacia Biotech "Biotrak cAMP EIA" kit (Cat. No. RPN 225) in accordance with the manufacturer's instructions. Compared to controls, HeLa cells show a 35 marked increase in intracellular cAMP after 24 hours of growth in the presence of EMD

(Fig. 2). This increase could still be observed after 120 hours in culture. The increase in intracellular cAMP suggests that cells grown in the presence of EMD generate internal signal(s) that could be part of pathways for growth regulation and differentiation.

5 (c) HeLa cells were harvested from cultures at 24, 48, 72, 96 or 120 hours (n=5 at each timepoint/experiment), washed in PBS and centrifuged. 200 µl of cells were lysed, and the level of apoptosis specific nucleic acid degradation products (histone associated DNA fragments) was quantified by sandwich ELISA using a Boehringer Mannheim "Cell Death Detection ELISA" kit (Cat. No. 1 774 425) according to the manufacturer's instructions. The
10 results are presented as the ratio between EMD treated cells and untreated cells. Hence values above 1 indicate induced cell death while values below 1 reflect prolonged cell survival. It appears from Fig. 3 that the HeLa cells show a marked increase in induced cell death when EMD is present in the cultures (values above 1), peaking at 72 hours after addition of EMD.

15

Based on these results, it is concluded that epithelial cell growth is poorer in the presence of EMD, and that the presence of EMD in the cultures increased programmed cell death more than two-fold.

CLAIMS

1. Use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the induction of apoptosis.
- 5 2. Use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the prevention or treatment of malignant or benign neoplasms.
- 10 3. Use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the prevention or treatment of cancer.
4. Use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the (selective) induction of apoptosis in neoplastic cells.
- 15 5. Use according to any of claims 1-4 wherein the preparation of active enamel substance is applied at or on tissue comprising a substantial proportion of epithelial cells.
6. Use according to claim 5 wherein said tissue comprises skin or mucosal tissue.
- 20 7. Use according to claim 6 wherein the mucosal tissue comprises oral mucosa, gastrointestinal mucosa, mucosa of the respiratory tract (such as lung mucosa), cervical mucosa or abdominal mucosa.
- 25 8. Use according to claim 5 wherein the tissue is glandular tissue, e.g. mammary gland, pancreas, liver, thyroid gland, bladder, prostate, sweat gland, salivary gland or pituitary gland tissue.
9. Use according to any of claims 1-4 for the topical treatment of cancer or neoplasms.
- 30 10. Use according to claim 8 wherein the cancer or neoplasm is selected from epithelial derived cancers or neoplasms.

- 11. Use according to claim 9 for application at or on a tumour site before, during or after a tumour operation to substantially reduce the risk of post-surgical metastasis or to substantially prevent recurrence of the tumour.
- 5 12. Use according to any of the preceding claims, wherein the active enamel substance is enamel matrix, enamel matrix derivatives and/or enamel matrix proteins.
- 13. Use according to any of the preceding claims, wherein the active enamel substance is selected from the group consisting of enamelins, amelogenins, non-amelogenins, proline-10 rich non-amelogenins, amelins (ameloblastin, sheathlin), tuftelins, and derivatives thereof and mixtures thereof.
- 14. Use according to any of the preceding claims, wherein the active enamel substance has a molecular weight of at the most about 120 kDa such as, e.g, at the most 100 kDa, 90 kDa, 80 kDa, 70 kDa or 60 kDa as determined by SDS Page electrophoresis.
- 15. Use according to any of the preceding claims, wherein the preparation of an active enamel substance contains a mixture of active enamel substances with different molecular weights.
- 20 16. Use according to any of the preceding claims, wherein the preparation of an active enamel substance comprises at least two substances selected from the group consisting of amelogenins, proline-rich non-amelogenins, enamelins, tuftelin, tuft proteins, serum proteins, salivary proteins, amelin, ameloblastin, sheathlin, and derivatives thereof.
- 25 17. Use according to any of the preceding claims, wherein the active enamel substance has a molecular weight of up to about 40,000.
- 18. Use according to any of the preceding claims, wherein the active enamel substance 30 has a molecular weight of between about 5,000 and about 25,000.
- 19. Use according to any of the preceding claims, wherein the major part of the active enamel substance has a molecular weight of about 20 kDa.

- - 20. Use according to any of the preceding claims, wherein at least a part of the active enamel substance is in the form of aggregates or after application *in vivo* is capable of forming aggregates.
- 5 21. Use according to claim 20, wherein the aggregates have a particle size of from about 20 nm to about 1 μ m.
- 10 22. Use according to any of the preceding claims, wherein the protein content of the active enamel substance in the preparation is in a range of from about 0.05% w/w to 100% w/w such as, e.g., about 5-99% w/w, about 10-95% w/w, about 15-90% w/w, about 20-90% w/w, about 30-90% w/w, about 40-85% w/w, about 50-80% w/w, about 60-70% w/w, about 70-90% w/w, or about 80-90% w/w.
- 15 23. Use according to any of the preceding claims, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
- 20 24. Use according to claim 23, wherein the pharmaceutically acceptable excipient is propylene glycol alginate.
- 25 20 25. Use according to claim 23, wherein the pharmaceutically acceptable excipient is hyaluronic acid or salts or derivatives thereof.
- 26. Use according to any of claims 1-25 of EMDOGAIN® or any proteins or peptides contained therein for the induction of apoptosis.
- 25 27. A method for inducing of apoptosis in neoplastic cells, the method comprising applying an effective amount of an active enamel substance at on on neoplastic cells.
- 28. A method for preventing or treating malignant or benign neoplasms, the method comprising administering to a mammal in need thereof a prophylactically or therapeutically effective amount of an active enamel substance.
- 30 29. A method according to claim 28, wherein the active enamel substance is applied in an amount of total protein per cm^2 area of affected tissue corresponding to from about 0.01 mg/ cm^2 to about 20 mg/ cm^2 , such as from about 0.1 mg/ cm^2 to about 15 mg/ cm^2 .

SEQUENCE LISTING

<110> Biora BioEx AB
<120> Matrix protein compositions for apoptosis
<130> 22776 DK 1
<160> 2
<170> FastSEQ for Windows Version 3.0
<210> 1
<211> 407
<212> PRT
<213> Unknown
<400> 1
Met Ser Ala Ser Lys Ile Pro Leu Phe Lys Met Lys Gly Leu Leu Leu
1 5 10 15
Phe Leu Ser Leu Val Lys Met Ser Leu Ala Val Pro Ala Phe Pro Gln
20 25 30
Arg Pro Gly Gly Gln Gly Met Ala Pro Pro Gly Met Ala Ser Leu Ser
35 40 45
Leu Glu Thr Met Arg Gln Leu Gly Ser Leu Gln Gly Leu Asn Ala Leu
50 55 60
Ser Gln Tyr Ser Arg Leu Gly Phe Gly Lys Ala Leu Asn Ser Leu Trp
65 70 75 80
Leu His Gly Leu Leu Pro Pro His Asn Ser Phe Pro Trp Ile Gly Pro
85 90 95
Arg Glu His Glu Thr Gln Gln Pro Ser Leu Gln Pro His Gln Pro Gly
100 105 110
Leu Lys Pro Phe Leu Gln Pro Thr Ala Ala Thr Gly Val Gln Val Thr
115 120 125
Pro Gln Lys Pro Gly Pro His Pro Pro Met His Pro Gly Gln Leu Pro
130 135 140
Leu Gln Glu Gly Glu Leu Ile Ala Pro Asp Glu Pro Gln Val Ala Pro
145 150 155 160
Ser Glu Asn Pro Pro Thr Pro Glu Val Pro Ile Met Asp Phe Gly Asp
165 170 175
Pro Gln Phe Pro Thr Val Phe Gln Ile Ala His Ser Leu Ser Arg Gly
180 185 190
Pro Met Ala His Asn Lys Val Pro Thr Phe Tyr Pro Gly Met Phe Tyr
195 200 205
Met Ser Tyr Gly Ala Asn Gln Leu Asn Ala Pro Gly Arg Ile Gly Phe
210 215 220
Met Ser Ser Glu Glu Met Pro Gly Glu Arg Gly Ser Pro Met Gly Tyr
225 230 235 240
Gly Thr Leu Phe Pro Gly Tyr Gly Gly Phe Arg Gln Thr Leu Arg Gly
245 250 255
Leu Asn Gln Asn Ser Pro Lys Gly Gly Asp Phe Thr Val Glu Val Asp
260 265 270
Ser Pro Val Ser Val Thr Lys Gly Pro Glu Lys Gly Glu Gly Pro Glu
275 280 285
Gly Ser Pro Leu Gln Glu Pro Ser Pro Asp Lys Gly Glu Asn Pro Ala
290 295 300
Leu Leu Ser Gln Ile Ala Pro Gly Ala His Ala Gly Leu Leu Ala Phe
305 310 315 320
Pro Asn Asp His Ile Pro Asn Met Ala Arg Gly Pro Ala Gly Gln Arg
325 330 335

Leu Leu Gly Val Thr Pro Ala Ala Ala Asp Pro Leu Ile Thr Pro Glu
340 345 350
Leu Ala Glu Val Tyr Glu Thr Tyr Gly Ala Asp Val Thr Thr Pro Leu
355 360 365
Gly Asp Gly Glu Ala Thr Met Asp Ile Thr Met Ser Pro Asp Thr Gln
370 375 380
Gln Pro Pro Met Pro Gly Asn Lys Val His Gln Pro Gln Val His Asn
385 390 395 400
Ala Trp Arg Phe Gln Glu Pro
405

<210> 2
<211> 324
<212> PRT
<213> Unknown

<400> 2
Met Lys Pro Asn Ser Met Glu Asn Ser Leu Pro Val His Pro Pro Pro
1 5 10 15
Leu Pro Ser Gln Pro Ser Leu Gln Pro His Gln Pro Gly Leu Lys Pro
20 25 30
Phe Leu Gln Pro Thr Ala Ala Thr Gly Val Gln Val Thr Pro Gln Lys
35 40 45
Pro Gly Pro His Pro Pro Met His Pro Gly Gln Leu Pro Leu Gln Glu
50 55 60
Gly Glu Leu Ile Ala Pro Asp Glu Pro Gln Val Ala Pro Ser Glu Asn
65 70 75 80
Pro Pro Thr Pro Glu Val Pro Ile Met Asp Phe Gly Asp Pro Gln Phe
85 90 95
Pro Thr Val Phe Gln Ile Ala His Ser Leu Ser Arg Gly Pro Met Ala
100 105 110
His Asn Lys Val Pro Thr Phe Tyr Pro Gly Met Phe Tyr Met Ser Tyr
115 120 125
Gly Ala Asn Gln Leu Asn Ala Pro Gly Arg Ile Gly Phe Met Ser Ser
130 135 140
Glu Glu Met Pro Gly Glu Arg Gly Ser Pro Met Gly Tyr Gly Thr Leu
145 150 155 160
Phe Pro Gly Tyr Gly Phe Arg Gln Thr Leu Arg Gly Leu Asn Gln
165 170 175
Asn Ser Pro Lys Gly Gly Asp Phe Thr Val Glu Val Asp Ser Pro Val
180 185 190
Ser Val Thr Lys Gly Pro Glu Lys Gly Glu Gly Pro Glu Gly Ser Pro
195 200 205
Leu Gln Glu Pro Ser Pro Asp Lys Gly Glu Asn Pro Ala Leu Leu Ser
210 215 220
Gln Ile Ala Pro Gly Ala His Ala Gly Leu Leu Ala Phe Pro Asn Asp
225 230 235 240
His Ile Pro Asn Met Ala Arg Gly Pro Ala Gly Gln Arg Leu Leu Gly
245 250 255
Val Thr Pro Ala Ala Ala Asp Pro Leu Ile Thr Pro Glu Leu Ala Glu
260 265 270
Val Tyr Glu Thr Tyr Gly Ala Asp Val Thr Pro Leu Gly Asp Gly
275 280 285
Glu Ala Thr Met Asp Ile Thr Met Ser Pro Asp Thr Gln Gln Pro Pro
290 295 300
Met Pro Gly Asn Lys Val His Gln Pro Gln Val His Asn Ala Trp Arg
305 310 315 320
Phe Gln Glu Pro

CELL DENSITY IN HUMAN EPITHELIAL (HeLa) CELL CULTURES




Fig. 1

INTRACELLULAR cAMP LEVELS IN HUMAN TRANSFORMED EPITHELIAL CELLS (HeLa)




Fig. 2

INDUCED CELL DEATH IN HeLa CELLS IN PRESENCE OF EMD[®]




Fig. 3